Nchi: Ufaransa
Lugha: Kiingereza
Chanzo: HMA (Heads of Medicines Agencies)
marbofloxacin 20 mg
Emdoka bvba
QJ01MA
Tablet
Fluoroquinolones
Dogs Non Food
2013-06-26
Issued: September 2013 AN: 00539/2012 Page 1 of 6 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Marbocare flavour 20mg tablets for dogs (UK and IE) Marbocare F 20mg tablets for dogs (FR) Odimar 20mg tablets for dogs (BE, LU, NL) Marbofloxacin WDT 20mg flavoured tablets for dogs (AT, DE) Marbofloxacino Emdoka 20mg tablets for dogs (ES) Marbofloxacina Emdoka 20mg tablets for dogs (PT) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION EACH TABLET CONTAINS: ACTIVE SUBSTANCE: Marbofloxacin 20.0mg EXCIPIENTS: For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet. Beige brown spotted round tablets with a cross-snap tab on one side. The tablet can be divided into halves or quarters. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Marbofloxacin is indicated in the treatment of the following infections caused by susceptible strains of organisms (see section 5.1); Skin and soft tissue infections (skinfold pyoderma, impetigo, folliculitis, furunculosis, cellulitis). Urinary tract infections (UTI) associated or not with prostatitis or epididymitis. Respiratory tract infections. Issued: September 2013 AN: 00539/2012 Page 2 of 6 4.3 CONTRAINDICATIONS Do not use in dogs aged less than 12 months, or less than 18 months for exceptionally large breeds of dogs, such as Great Danes, Briard, Bernese, Bouvier and Mastiffs, with a longer growth period. Do not use in cats. For the treatment of this species, a 5 mg tablet is available. Do not use in animals with known hypersen Soma hati kamili